VTRS — Viatris Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $19.91
- YTD price return
- +59.92%
- YTD total return
- +63.69%
- Market cap
- 22.8B
- Enterprise value
- 34.6B
- Shares outstanding
- 1.1B
- 52W low
- $9.92
- 52W high
- $19.96
- From 52W high
- -0.25%
- From 52W low
- +100.71%
- 52W range
- 100%$9.92–$19.96
- Beta
- 0.90
Volume
- Rel volume
- 1.56×
- 30D volume
- 9.2M
- 30D $ vol
- 169.1M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- none
- Insider net 1Y
- −$1.1M
Form 4 transactions by trade date, as filed; latest on file 2026-06-25.
Fundamentals
- Sales (ttm)
- 14.7B
- Sales/share
- $12.85
- FCF (ttm)
- 2.1B
- FCF/share
- $1.84
- Book value/share
- $11.94
- Debt / equity
- 0.85×
- Current ratio
- 1.55
Growth (CAGR, ttm) · 10Y
- Sales
- +4.27%-1.62%-3.02%n/a
- FCF
- +27.15%+0.19%-0.40%n/a
- Shares
- -0.46%-1.50%-1.06%n/a
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- +4.75%-0.12%-1.98%n/a
- FCF/share
- +27.74%+1.71%+0.67%n/a
- Book value/share
- -9.66%-11.79%-7.35%n/a
- Dividend/share
- +0.00%+0.00%+8.21%n/a
- Price
- +97.03%+29.29%+7.71%-5.48%
- Total return
- +104.02%+34.84%+12.34%-3.33%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/OI (ttm)
- 135.6×
- Fwd P/E
- 7.0×
- P/S (ttm)
- 1.5×
- P/B (mrq)
- 1.7×
- P/FCF (ttm)
- 10.8×
- EV/EBITDA (fy)
- 12.3×
- EV/Sales (ttm)
- 2.4×
- FCF yield (ttm)
- 9.25%
- Dividend yield (fwd)Div yield
- 2.41%
- Dividend yield (ttm)
- 2.41%
- Dividend/share (fwd)
- $0.48
- Buyback yield (realized, 1y)
- 0.46%
- Shareholder yield (realized, 1y)
- 2.87%
- Buyback yield (cash, ttm)
- 1.68%
- Shareholder yield (cash, ttm)
- 1.68%
Vs own 10Y history
- P/OI
- 92nd
- P/S
- 100th
- P/B
- 100th
- P/FCF
- 94th
Bar = where today’s multiple sits in VTRS’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-06#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y n/m5Y n/mYoY +46.3%EPS (diluted)
5Y n/m5Y n/mYoY n/mFree cash flow
5Y CAGR +14.4%5Y CAGR +14.4%YoY +23.6%TTM: operating cash flow $2.5B, capex −$374.9M
Q3 2026: operating cash flow $899.4M, capex −$85.7M
Shares (diluted)
5Y +133.7%5Y +133.7%YoY −1.4%Dividend per share
YoY +0.0%About Viatris#
Data provided bySource: Twelve DataViatris Inc. is a global healthcare company that develops, manufactures, and markets prescription medicines across a broad range of therapeutic areas. Its portfolio includes branded medicines, generic drugs, complex generics, and biosimilars, serving patients and healthcare providers in developed and emerging markets. The company also supplies active pharmaceutical ingredients used in pharmaceutical manufacturing and supports access to medicines through broad commercial and distribution capabilities. Viatris Inc. operates across regions including North America, Europe, Greater China, Japan, Australia, New Zealand, Latin America, Africa, and the Middle East. Its products address conditions in areas such as cardiovascular health, infectious diseases, central nervous system disorders, immunology, and oncology. By combining established brands with off-patent and technically complex medicines, Viatris Inc. occupies an important role in the global pharmaceutical market, helping manufacturers, healthcare systems, and patients access a wide range of essential treatments.
Canonsburg, PA·30,000 employees·Drug Manufacturers - Specialty & Generic·viatris.com·As of Oct 28, 2026
Recent filings#
- Nov 5Earnings · Earnings release — EPS $0.71 vs $0.64 est. (+10.9%); revenue $3.75B (−0% y/y) 1.3%
- Oct 88-K · Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
- Aug 6Earnings · Earnings release — EPS $0.69 vs $0.62 est. (+11.3%); revenue $3.76B (+5% y/y) 7.7%
ETFs holding VTRS#
31 of the 193 ETFs ChartRow carries live hold VTRS. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| SPYD | SPDR Portfolio S&P 500 High Dividend ETF | 1.5% |
| COWZ | Pacer US Cash Cows 100 ETF | 0.5% |
| VBR | Vanguard Small-Cap Value ETF | 0.4% |
| XLV | Health Care Select Sector SPDR Fund | 0.3% |
| VHT | Vanguard Health Care ETF | 0.3% |
| VB | Vanguard Small-Cap ETF | 0.2% |
| RSP | Invesco S&P 500 Equal Weight ETF | 0.2% |
| IWS | iShares Russell Mid-Cap Value ETF | 0.2% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +16.98% | -0.79% |
| JNJ | Johnson & Johnson | +8.42% | +1.43% |
| ABBV | AbbVie Inc. | +9.23% | +1.07% |
| MRK | Merck & Co. Inc. | +3.37% | -0.14% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +4.74% | -0.40% |
| NVS | Novartis AG | +15.46% | +0.38% |
| TMO | Thermo Fisher Scientific Inc. | +5.81% | +2.63% |
| AMGN | Amgen Inc. | +14.36% | +0.03% |
